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Successful clinical treatment outcomes rely on achieving optimal systemic 
delivery of therapeutics. The oral route of administering Active Pharmaceutical 
Ingredients (API) remains formidable because of ease to the patient and conve-
nience. Yet, the gastrointestinal tract (GIT) poses several barriers that need to be 
surmounted prior to systemic availability, especially for Class IV type drugs. Drug 
delivery systems in the form of nanoparticles (NP), can be appropriately formu-
lated to alter the physicochemical properties of APIs, thereby addressing constraints 
related to absorption from the GIT. Polymers offer amenability in the fabrication 
of NP due to their diversity. Chitosan has emerged as a strong contender in orally 
deliverable NP because it is biocompatible, biodegradable and muco-adhesive. Due 
to the positively charged amine moieties within chitosan (NH3
+), interactions with 
the negatively charged sialic acid of mucin within the mucosa is possible, which 
favors delayed GI transit and epithelial uptake. This ultimately results in improved 
systemic bioavailability. Thus, we expect research in the use of chitosan in oral NP 
delivery to intensify as we transcend the frontier toward clinical testing of viable 
formulations.
Keywords: chitosan, gastrointestinal, cellular uptake, nanoparticles, drug delivery, 
formulation
1. Introduction
According to the US National Institute of Health, drug delivery is a process that 
permit the influx of therapeutic substances in to the body. Drug delivery systems 
are designed to enhance the efficiency and safety of therapeutics by regulating 
the rate, time and place of release in the body [1, 2]. Drug delivery technology has 
emerged as an essential tool for the improvement of drug bioavailability, reduction 
in the side effects of medication, all of which generate remarkable clinical outcomes 
[3]. Drugs may be administered to the body via local application, enterally or 
parenterally. The parenteral route typically relates to administration that excludes 
absorption from the gastrointestinal tract (GIT). It consists of administration by 
injection, inhalation and via transdermal routes. The enteral route is associated 
with the absorption of the drug via the GIT, this includes oral, sublingual, and rec-
tal administration. Aptly, the mode of drug administration depends on the disease, 
the desired therapeutic effect and the nature of the product available [4]. Moreover, 
each delivery route has inherent benefits and constraints. Nevertheless, the major-
ity of manufactured medicines in the pharmaceutical industry are delivered orally, 
owing to the distinctive advantages offered by this route, including versatility in 
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accommodating various types of drugs, simplicity of administration and acces-
sibility, patient compliance and safety profiles [5–7]. Additionally, the intestinal 
epithelium is an ideal platform for drug absorption due to the viscous mucosal layer 
lined with abundant enterocytes, goblet cells, and Peyer’s patches that trap drug 
molecules within the mucus as they transit the GIT. [8, 9].
In comparison to other routes of administration, the oral route is exceptionally 
complex in expression of anatomical features physiology throughout the GIT [10]. 
Furthermore, these expressions vary along the GIT in both intensity structure. For 
example, the mucus layer varies in composition and physical properties along the 
GIT and the pH varies significantly in the main sections of the GIT. The gastroin-
testinal motility also varies in intensity and form along the GIT and also depends on 
food status [11]. Even though, these features can impede drug delivery across the 
GIT, through careful interplay between formulation science and GIT physiology, 
scientists have been able to exploit this variance for improved drug delivery. In this 
regard, nanoparticle formulations have immerged as strong contenders able to sur-
mount some of the constraints associated with GIT absorption. Nanoparticles have 
gained great interest by researchers in recent years as they can be used to improve 
drug solubility and bioavailability in the harsh GIT environment due to increased 
surface area to volume ratio, thus provide a rapid onset of therapeutic action [12]. 
They can also be used to targeting specific sites within the GIT and hence reduce the 
effects of enzymatic degradation, all of which can improve the safety and effective-
ness of drugs [12, 13].
Nanoparticle formulations may be presented in various forms however, polymeric 
nanoparticles present the versatility of polymers and can be tailored to achieve 
superior drug stability, enhanced drug payload capacity, longer circulation times 
and controlled drug release capabilities, when compared with other their colloidal 
counterparts [14, 15]. In this regard, chitosan-based nanoparticle formulation have 
been shown to present several of the desirable attributes listed above in addition to 
being biodegradable, having low toxicity, amenable to tuneable physical properties 
and bio-adhesive properties [16, 17].
In this chapter we will be discussing the interplay between the GIT physiology/
anatomy and drug physicochemical/biopharmaceutical factors in the absorption 
process that influence oral therapeutics. We, will also review the physicochemi-
cal properties of chitosan relevant for effective GIT delivery, including methods 
of formulation. The most utilised nanoparticle formulation methods used for 
chitosan-based nanoparticles are also examined. Finally, we will highlight the 
recent developments on chitosan-based nanoparticles used in the oral delivery of 
different drugs.
2. The GIT
The GIT, also known as the digestive tract or alimentary canal, is approximately 
9 meters long and can be functionally divided into two parts, the upper and the 
lower GIT (Figure 1). The upper GIT; consisting of mouth, pharynx, oesophagus, 
stomach and small intestine, play a major role in the transport of the swallowed 
food bolus, enzymatic digestion and absorption of nutrients [18]. The lower GIT is 
usually referred to the large intestine and is responsible for the adsorption of water, 
fermentation of undigested sugars and the storage and evacuation of stool [19]. 
Following oral dosing, the drug traverses several semipermeable cell membranes 
through its trajectory to absorption and eventually enters the general circulatory 
system. Drugs cross cell membranes, which comprise of bimolecular lipid matrix, 
either by passive diffusion or active transport.
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2.1 Passive diffusion
The most prevalent form of absorption of the majority of orally administered 
drugs is by passive diffusion across cell membranes. This process comprises of a 
three-step process, whereby the permeant first transverses into the membrane, dis-
perses across it and then is released into the cytosol [20]. Typically, drug molecules 
move down a concentration gradient, from a region of high concentration (e.g., GI 
fluids) to one of low concentration (e.g., blood), without the expenditure of energy 
[21]. Usually, a concentration gradient is manifested as a disparity in concentration 
of a substance within an area and is linearly related to the diffusion rate. The latter 
is also governed by the lipid solubility, size and polarity of the drug species.
Most drugs are either weak acids or bases and occur either in the unionized or 
ionized form as a function of pH [22]. For lipophilic drugs, the unionized form 
of drug, may penetrate cell membranes easily as the membrane is lipoidal. On the 
other hand, hydrophilic drugs, present an ionized form of the drug, which has 
high electrical resistance and thus cannot traverse the cell membranes easily but 
may diffuse through the para-cellular spaces. However, it is worth noting that the 
para-cellular junctions contribute to less than 0.01% of the entire GIT surface area 
and furthermore, the permeability of these junctures diminishes down the GIT 
[23]. Additionally, the capability of drugs to traverse a membrane also relies on the 
acid–base dissociation constant (pKa) of the drug in question. The pKa is the pH at 
which concentrations of ionized and unionized forms are equivalent [24]. So, if the 
pH is less than the pKa, the unionized form of a weak acid prevails, and vice versa 
for weak bases. Henceforth, when a weak acid is administered orally, nearly all the 
drug in the stomach remains unionized, preferring diffusion via the gastric mucosa. 
On the other hand, for a weak bases with a pKa = 4.4, majority of the drug in the 
stomach will be ionized [21].
Overall, the process by which molecules traverse cell membranes is by passive dif-
fusion, down the concentration gradient. However large hydrophilic ionic molecules 
and charged molecules cannot freely traverse the phospholipid bilayer cell mem-
brane passively. Their transport may be confined to protein channels and distinct 
transport mechanisms present within the membrane [25]. Such drugs gain access 
through the membrane by facilitated diffusion whereby molecules integrate with 
embedded protein carriers to shuttle them across the membrane. This process does 
not expend energy and is also down the concentration gradient though quicker than 
Figure 1. 
The anatomy of the human gastrointestinal tract.
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would be anticipated by diffusion alone [26]. A frequent case of facilitated diffusion 
is the migration of glucose into cells during the production of adenosine triphosphate 
(ATP). Glucose is both large and polar thereby unable to pass the lipid bilayer via 
simple diffusion. Hence, glucose molecules are delivered into the cell via a unique 
carrier protein (glucose transporter) to promote its internalisation in cells [27].
2.2 Active Transport
Active transport is an energy-dependent process that translocates drug molecules 
against their concentration gradient by a molecular pump [20]. Carrier-mediated 
active transport demand energy via ATP hydrolysis or by accompanying the co-
transport of counter ions down its electrochemical gradient (e.g., Na+, H+, Cl−) 
[28]. The most common active transport system is the sodium-potassium pump and 
receptor-mediated endocytosis. Energy can either be directly provided to the ion 
pump or indirectly by connecting a pump-action to an activated ionic gradient. It 
is often encountered in the gut mucosa, the liver, renal tubules and the blood–brain 
barrier [22]. Active transport is typically restricted to drugs that structurally resem-
ble endogenous substances; e.g., vitamins and amino acids, and that are absorbed via 
specific sites in the small intestine. Targeting drugs to these transporters can enhance 
their bioavailability and distribution [21].
The sodium-potassium pump system (Na+/K+ ATPase), utilises ATP to move 
Na+ and K+ in and out of the cell. It is a vital ion pump located in the membranes of 
various cell types, such as the Na+/amino acid symport in the mucosal cells of the 
small bowel [22, 29].
Cells control the endocytosis of certain substances via receptor-mediated endo-
cytosis. The use of this form of endocytosis in the GIT is crucial for oral delivery of 
drugs because it delays the transit of drugs in GIT. Receptor-mediator endocytosis 
involves the internalisation of macromolecules by binding the latter to receptors 
considered as membrane-associated protein [30]. There are more than 20 differ-
ent receptors involved in the internalisation of macromolecules [31]. Following 
binding to the receptor on the cell surface, the cell will endocytose the portion of 
the cell membrane enclosing the receptor-ligand complex via a clathrin-dependent 
endocytic process [28]. Clathrin plays a significant role in the formation of clathrin-
coated pits; invaginated regions of the plasma membrane, and pinch off to form 
clathrin-coated vesicles that transport molecules within cells [31].
In summary, drug adsorption may occur passively or via active transport. 
In either case, absorption occurs predominantly in the small intestine due to its 
more permeable membrane and larger surface area provided by the microvilli. 
Even though, the stomach has a relatively broad epithelial surface, yet the dense 
mucus layer and transient transit times expended by dosage forms contribute to 
an impeded absorption. Moreover, the colon with an absorptive surface area of 
about 5m2 has negligible contribution to drug absorption in GIT, due to slow caecal 
arrival times of dosage forms, the presence of numerous gut bacteria and solid 
stool that impede lateral diffusion. All in all, absorption of oral drugs is interlinked 
and controlled by various intrinsic factors; like drug solubility, dissolution and 
permeability across the mucosal barriers, and physiological factors; such as gastro-
intestinal transit time, pH and gut microbiome [13, 32].
2.3 Drug dissolution, solubility and permeability
Drug dissolution, solubility and permeability are the three fundamental param-
eters used in the Biopharmaceutics Classification System (BCS) to predict the 
factors limiting drug absorption from GIT [33]. The BCS is recognised as a useful 
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tool for designing drug delivery systems and is adopted by the US Food and Drug 
Administration (FDA), the European Medicines Agency (EMA) and the World 
Health Organization (WHO) [34]. According to the BCS, all drug substances are 
classified into four categories: class I—high soluble and high permeable, class II—
low soluble and high permeable, class III—low soluble and high permeable and class 
IV—low soluble and low permeable [35].
Drug solubility is crucial outcome in pharmaceutical dosage form. In the BCS 
system, a drug is deemed highly soluble when the maximal dose strength is soluble 
in 250 mL of aqueous media across the pH range of 1 to 7.5 [35]. However, more 
than 40% of the established new chemical entities in the pharmaceutical sector are 
considered insoluble in water, causing inadequate bioavailability [36]. This makes 
solubility amongst the most important rate limiting parameters in GIT absorption.
Drug dissolution reflects a dynamic consequence to drug absorption [33], 
whereby drug is released, dissolved and made accessible for absorption. With the 
exception of enteric formulations and drugs with low acid solubility, the dissolution 
process for majority of drugs starts in the stomach where the volume of gastric fluid 
is sufficient to attain effective drug dissolution [37]. Thus, the gastric fluid contain-
ing the disintegrated immediate-release dosage forms brings the solubilized drug 
into contact with the absorptive surface of the small intestine as absorption in the 
stomach is generally minimal.
Drug permeability represents the final frontier in the sequence of rate-liming 
steps to systemic drug availability. It is a measure of the ease of permeation of the 
drug across the intestinal wall. There is a positive association between the intestinal 
permeability and drug solubility GI milieu, which in turn depends on the physico-
chemical characteristics of the drug [38], including the pKa, particle size, lipophi-
licity, as discussed in the sections below. The ultimate amount of drug absorbed 
from the GIT also bears dependence on its transit time in the GIT [39].
2.4 Gastrointestinal pH
The GI pH influences the extent of ionization of drug molecules and thereby 
impacts on its absorption across the epithelium. Variations in pH across the GIT 
can be exploited for delayed drug release in desired section of the GIT in order to 
achieve efficient absorption. The fasted stomach is acidic, with pH range of 1–3, 
which increases upon food or liquid intake. Food is known to buffer the acidic 
content of the stomach. A rise in pH resumes in response to the continual gastric 
secretion and then finally, the pH reverts to the original levels due to gastric emp-
tying of content; [40]. The gastric emptying rate significantly affects the rate of 
drug absorption because it regulates arrival in the duodenum, where the epithelial 
surface is suited for absorption [41]. Moreover, the disparity in gastric pH condi-
tions affects the drug delivery behaviour of modified release dosage forms such as 
enteric coated products, where the onset of release along with the overall release 
kinetics may be changed [42].
The arrival of orally administered dosage forms into the small intestine is met by 
a pH of about 6 in the duodenum through to pH 7.4 at the terminal ileum [43]. This 
high pH variability is due to duodenal secretion of alkaline bicarbonate. During 
postprandial state, the initial intestinal pH drops due to the influx of acidic chyme, 
which is buffered by bicarbonate secretion as it travels distally [13]. Besides, the 
mean pH in proximal small intestine during the first hour of transit is usually 6.6, 
which is further decreased to 5–6 in the distal duodenum [44].
Typically, the pH in the caecum drops to just below pH 6 owing to the fermenta-
tion processes of the colonic microbiota and then rises to pH 7 at the rectum [42]. 
The drop in the amount of short chain fatty acids at the distal colon causes the 
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secretion of colonic mucosal bicarbonate that leads to a neutral pH. Short chain 
fatty acids are the end products of fermentation of dietary fibres by the anaerobic 
intestinal microbiota [45]. As a consequence of the neutral pH of the colonic 
luminal fluid, the solubilisation of drug is the rate-limiting factor in colonic drug 
absorption [46]. The unspecific interactions of drugs with colonic content (e.g. 
dietary residues, intestinal secretions or faecal matter) all adds to the odds of effec-
tive adsorption across the colon [47].
2.5 GIT transit time
Generally, the GIT transit time of most orally administered doses through 
buccal cavity and oesophagus is transient. The stomach is naturally the first seg-
ment of the GIT, wherein disintegration and dissolution of solids such as drugs and 
formulations occur [42]. The period required for a dosage form to exit the stomach 
is inconstant and relies on several physiological factors, such as age, body posture, 
gender and food intake [48]. Gastric transit can span from 0 to 2 h in the fasted 
state and can be extended up to 6 h after food intake [47]. The small intestine is 
the region of choice for drug absorption with a transit time ranging from 2 to 6 h 
in healthy individuals. The dissolution of poorly soluble, weakly acidic compounds 
and lipophilic compounds is greatly enhanced in this region [13]. In colon-specific 
drug delivery, the drug has to cross the whole GIT prior to arrival at the colon. 
Thus, the transit time across the colon can be highly variable, and ranges from 20 
to 56 h in healthy humans, although higher variations are also reported in literature 
amounting up to 72 h [42, 49, 50]. Variations in colonic transit time are affected by 
dosing time, bowel movements as well as gender, whereby females generally have 
longer colonic transit times than males [51, 52].
2.6 Gut microbiome
Enzymatic and microbial degradation of GIT content affects the amount 
ultimately made available for absorption. The active sites for most endogenous 
enzymes are the stomach and small intestine. Even though these enzymes may 
affect the stability of orally administered drugs, it is possible to exploit this property 
for regional drug delivery of formulations in the GIT [47]. On the other hand, the 
intestinal microbiome which includes 500–1000 bacterial species is also important 
for the digestion of food and the metabolism of drugs [53]. Gastrointestinal micro-
biome is found in both upper and lower GIT, whereby, a lower bacterial number 
(1013–1014 bacteria mL−1 of intestinal content) is in the upper GIT because of the fast 
luminal flow, intestinal fluid volume, and the secretion of bactericidal compounds 
in this part of the GIT, and highest bacterial community (1010–1011 bacteria mL−1 of 
intestinal content) is in the colon, in which the redox potential is low and the transit 
time is long [54, 55]. Therefore, greater number of the intestinal microbiome exists 
in the anaerobic colon, in which the fermentation of carbohydrates contributes to 
their nourishment. Usually, orally administered drugs are transformed to bioac-
tive, bio-inactive, or toxic metabolites by the gut microbial population, all of which 
can impede the bioavailability of drug. However, gut microflora can improve drug 
bioavailability by eliminating polar moiety from derived conjugates and thereby 
promoting biliary recycling of compounds [13].
Thus, formulation scientist must be cognizant of the interplay between drug 
and physiological and anatomical manifestations within the GIT when designing 
orally administered dosage forms. For example, enteric coating can be applied to 
dosage forms to delay the release of the API in the acidic gastric fluid until pH above 
5.0 [56]. Enteric coating may also be used to shield acid-labile drugs from gastric 
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distress, and upon arrival to the alkaline pH milieu, the enteric polymer coating 
disintegrates within the intestinal fluid, releasing the drug [57]. Despite employing 
such coatings and other conventional interventions, numerous pharmaceuticals 
still display insufficient bioavailability through the oral route of administration. 
This necessitates the use of alternate strategies. One area of research that is gaining 
traction more recently is the employment of nanoparticles.
3. Nanoparticle technology
Nanoparticle technology is a multidisciplinary field that utilizes principles from 
chemistry, biology, physics and engineering to design and fabricate submicronic 
(< 1 μm) colloidal systems [58]. Nanotechnology has several pharmaceutical and 
medical applications wherein nanoparticles (NPs), with sizes comparable to large 
biological molecules such as enzymes can be employed in the delivery of therapeutic 
agents [59]. The effectiveness of the nanoscale drug delivery vehicles lies on their 
ability to attain the following key attributes [60]:
• The NP must be able to bind or contain the appropriate drug.
• The nanocarrier must stay stable in the serum to allow systemic delivery of the 
therapeutics and only release the drug once at the required site.
• The NP-drug complex has to reach the required site either via receptor-medi-
ated interactions or by the enhanced permeability and retention (EPR) effect.
• The residual NP carrier should ideally be made of a biological or biologically 
inert material with a limited lifespan to allow safe degradation.
There are several types of NP drug delivery systems, which may be broadly 
divided as organic and inorganic NPs [61]. Their particle size, surface charge  
(ζ potential), hydrophilicity/hydrophobicity, composition, etc. can be tailored 
for a diverse applications [62]. The primary consideration when designing orally 
administered NP drug delivery system is to maximise drug concentration in the GI 
therapeutic window.
3.1 Oral organic NP
Organic NP (Figure 2) are solid particles comprised of organic compounds 
(usually lipidic or polymeric) ranging from 10 nm to 1 μm [63]. They can be 
formulated by simple techniques to encapsulate therapeutic agents. Preferably, 
compounds used in formulation of organic NPs should be biodegradable and 
biocompatible [61]. Manifestations of organic NP include liposomal, polymeric and 
solid lipid NP, each system possessing requisite features that addresses physiological 
and anatomic constraints addressed in sections above. In addition, others systems 
such as micelles, dendrimers etc. have been also explored as effective nanocarriers 
for effective deployment of APIs in the GIT [14, 64].
3.2 Oral inorganic NP
Inorganic NP represent a wide spectrum of systems synthesized from metals, 
metal oxides, and metal sulphides [65]. Gold, silica and superparamagnetic oxide 
NP are among the long list of inorganic NP (Figure 3). They have been studied for 
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use in imaging on nuclear magnetic resonance and high-resolution superconducting 
quantum interference devices, and their intrinsic properties have been utilised for 
therapy [66]. Inorganic NP can easily be conjugated to ligands for tumour target-
ing and/or with chemotherapeutics for tumour therapy. Additionally, their surface 
composition can be feasibly manipulated to create NP that can escape the reticulo-
endothelial system [67]. Even though inorganic NP present good stability character-
istics, they have not been the focus of attention in oral NP research, possibly due to 
concerns on the degradation and elimination end products, which can be potentially 
toxic [68].
Generally, inorganic NPs differ conceptually from organic NPs in terms of 
fabrication principles. Inorganic NPs can be formed by the precipitation of inor-
ganic salts, which are linked within a matrix, whilst, most organic NPs are formed 
by several organic molecules through self-organization or chemical binding [61]. 
Notwithstanding, both types of NP are very promising in the formulation of oral 
Figure 2. 
Examples of organic nanoparticle platforms for drug delivery.
Figure 3. 
Examples of inorganic NP platforms for drug delivery.
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delivery system and forms part of the evolutional success in several clinical applica-
tions. Polymeric NP arguably presents more desirable attributes as orally delivered NP 
because of their higher stability, enhanced drug payload and controlled drug release 
capabilities compared with their colloidal counterparts [14, 69].
3.3 Polymeric NP
According to Alexis F. et al., polymeric NP represent the most effective nano-
carrier system for prolonged drug delivery [70]. ‘Polymeric NPs’ include any type 
of polymer formed as NP. Nanospheres are solid spherical NP with molecules 
attached or adsorbed to their surface, whilst nanocapsules are vesicular systems 
with substances confined within a cavity consisting of a liquid core (either water 
or oil) surrounded by a solid shell [71]. Characteristic properties of polymers such 
as molecular weight, hydrophobicity and crystallinity can be explored to mani-
fest controlled drug release kinetics and entrapment of therapeutic agents [72]. 
Polymers also provide significant flexibility in the design of oral NP and many 
exhibit biodegradability [73]. In this regard, synthetic and natural variants have 
been studied. For example poly-lactic-co-glycolic-acid (PLGA) and poly-lactic-acid 
(PLA) are synthetic whilst natural polymers include gelatine, dextran, and chitosan 
[74]. The use of natural polymers is preferred over the synthetic ones as the former 
usually exhibit less toxicity, widely available and have lower production costs [75]. 
Chitosan is arguable one of the most studied polymer in NP formulation in view of 
its distinctive properties. In orally administered NP, chitosan offers added desir-
ability including muco-adhesiveness, augmenting the dissolution rate of poorly 
water-soluble drugs; useful in drug targeting in the GIT [76].
4. Chitosan polymer
Chitosan is a hydrophilic, cationic polysaccharide soluble in dilute acids such as 
acetic acid and formic acid, due to protonated amine groups (NH3+) [75]. It is an 
N-acetylated derivative of chitin, a natural polysaccharide found in the shells of 
marine crustaceans. Chitin is chemically inert and thus has fewer applications that 
chitosan [77]. The acetamido group of chitin, (C2H4NO) can be turned into amino 
group to yield chitosan by the alkaline deacetylation of chitin. Chitosan is approved 
as safe by the United States Food and Drug Administration (US-FDA) for dietary 
use and wound dressing applications, but its toxicity increases with electrical 
charge and degree of deacetylation [17]. Chemically, it comprises of β- [1–4] -linked 
D-glucosamine and N-acetylated units (Figure 4).
The amine group has pKa of 6.2–6.5 [78]. At slightly acidic pH values, the amine 
groups (NH3+) become protonated, hence possessing the ability to effectively form 
electrostatic interactions with negatively charged species within mucin in the GIT 
[75]. Positively charged moieties of chitosan also interact with the tight junctions 
of the intestinal epithelial cells and thus modulate drug permeation and absorption 
through the interstitial space between epithelial cells [79]. Moreover, the existence 
of both hydroxyl and amino groups offers various possibilities for chemical modifi-
cation. Chemical modifications give rise to different functional derivatives of chi-
tosan like carboxylation, thiolation, alkylation, acylation etc. that further imparts 
desirable physiochemical and biopharmaceutical properties, such as solubility, 
adsorption and pH sensitivity in oral drug delivery [80]. For example, N-trimethyl 
chitosan chloride is developed to amplify the intestinal solubility of chitosan; 
thiolated chitosan is produced to augment the mucoadhesiveness of chitosan; 
Chitin and Chitosan - Physicochemical Properties and Industrial Applications
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quaternization of chitosan reinforces its impact on the tight junctions of the GIT 
epithelium whilst grafting carboxylated chitosan with poly(methyl methacrylate) 
imparts increased pH sensitivity [81]. Physical modification through blending with 
other polymers may be used to enhance desirable physical properties. For example, 
blending of chitosan with polyethylene glycol (PEG) and polyvinyl alcohol (PVA) 
ameliorate the hydrophilic property of chitosan, while blending of chitosan with 
cellulose improves its antibacterial properties [82].
4.1 Mucoadhesion from chitosan
Some of the key desirable features in orally administered dosage forms 
is delayed GI transit in the duodenum and ability to traverse the epithelium 
effectively. In this regard, chitosan-based NP have been shown to possess these 
attributes. Mucoadhesion refers to the adhesion between two materials, one of 
which is mucosal [83]. It can be utilised to prolong the GI transit of dosage forms 
in the duodenum, thereby improving bioavailability. Delayed transit results from 
interactions of positively charged moieties in chitosan with negatively charged 
moieties in sialic acid within mucin [81]. Chitosan is also capable of physically 
penetrating the mucous network. Prolonged GI residence results in higher net 
drug flux across the GIT membrane. Drug flux is a combination of passive diffu-
sion and uptake of whole NP by Peyer’s patches [84]. Moreover, chitosan offers 
controlled drug release capabilities via diffusion from the matrix. Yin et al. 
prepared thiolated trimethyl chitosan NP for the oral delivery of insulin, where 
increase in the mucoadhesion resulted in increased insulin transport through rat 
intestine and uptake by Peyer’s patches compared to controls. They attributed 
these results to the disulfide bond formation between the NP and mucin [85]. 
Overall, to achieve the desired properties of interest such as particle size, particle 
size distribution and area of application, the mode of preparation of chitosan NP 
plays an essential role.
4.2 Fabrication methods for chitosan NP
The preparation of chitosan NP is principally divided into two approaches. The 
first approach is based on a two-step procedure, where an emulsification system 
is carried out to generate nanodroplets in which organic compounds (polymer, 
monomer, and lipid) are solubilized, followed by precipitation or polymerisation 
into NP [61]. The second approach involves a one-step procedure where the NP 
are directly generated via different mechanisms such as nanoprecipitation or ionic 
gelation [86]. An example of each of the two general approaches is summarized in 
the following.
Figure 4. 
Chemical structure of chitosan, comprising N-acetyl-D-glucosamine (right) and D-glucosamine (left) units.
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4.2.1 Chitosan NP by ionic gelation
Ionic gelation, also known as ionotropic gelation or polyelectrolyte complex-
ation involves the gradual addition of a cross-linking agent (tripolyphosphate, 
glutardehyde etc.) into an aqueous solution of chitosan under continuous stirring 
to form hydrogels [87]. The polyanions from the cross-linker forms a meshwork of 
structures by interacting with the polyvalent cations within chitosan, leading to 
gelation [88]. APIs can be loaded into these hydrogels during the production where 
it becomes encapsulated or added to the formed NP, where it can be adsorbed into 
the matrix. The choice of the cross-linker should be matched to the desired physical 
characteristics of the NP, such as mechanical strength, as well as safety profiles. For 
example, glutardehyde reported to be toxic when used in high concentrations and 
results in NP with low mechanical strength. This has been attributed to its double 
bond (–C=N–) association with the amine group in chitosan [89]. Genipin is a 
natural cross-linker obtained from iridoid glucoside (geniposide) and present in 
gardenia fruits that can be cross-linked with chitosan. It displays slower degradation 
rate than glutaraldehyde and possess higher biocompatibility. Sodium tripolyphos-
phate (STPP) displays better crosslinker characteristics than each of the above 
because of its inorganic nature and consequently, results in production of chitosan 
NP with better mechanical stability. The size dimension derived from STPP gelled 
chitosan NP is of lower order as well. Another attractive feature of STPP is that it is 
nontoxic, relatively inexpensive, multivalent, has quick gelling property and thus, 
widely utilised as a crosslinker in chitosan-based NP [90–92].
4.2.2 Emulsion evaporation
Polymeric nano-emulsions are formulated whereby organic solvent is added to 
a solution of chitosan with surfactant and mixed via sonication [93]. Basically, the 
emulsion droplets are converted into NP suspension as the organic solvent evapo-
rates by continuous magnetic stirring at room temperature. The NP suspensions are 
then centrifuged, washed with distilled water to remove additives such as surfac-
tants and finally lyophilized [94]. Poovi et al. encapsulated the poorly water-soluble 
drug, repaglinide, into chitosan NP using the emulsion evaporation for sustained 
release. They proved that the NP exhibited a controlled release of repaglinide and 
obtained a high drug loading (11.22% w/w) and encapsulation efficiency (97.0%) 
[95]. In another study, Lee et al. employed solvent evaporation method to formulate 
polymeric NP from chitosan derivatives fluorescein isothiocyanate (FITC) - con-
jugated glycol CSs (FGCs) using diluted chloroform as the solvent. Size range of 
150–500 nm were obtained and the NP remained stable in phosphate buffered 
saline for 20 days at 37°C [96].
4.3 In vitro drug release from chitosan NP
In vitro drug release studies give us insights on the response of formulated 
delivery systems to challenges in in vivo. The rate and extent of in vitro drug release 
from chitosan-based NP is influenced by a host of factors, notably, shape and size 
of the of the delivery system, physicochemical properties of the drug and external 
media [97]. Three primary mechanisms govern the drug release from chitosan NP, 
which includes desorption (release of drug from surface), diffusion, and erosion/
degradation of the particle matrix [98]. Erosion or degradation of polymers lead to 
successive physical depletion of the polymer as chains and bonds break [99]. Drug 
release from the chitosan NP matrix is often pH dependent because of the solubility 
of chitosan in acidic media [100]. In acidic media, the matrix swells or disentangles 
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and may act as an effective barrier to drug diffusion. The extent of drug diffusion 
through this gelled matrix depends on the diffusivity of the drug [99]. In alkaline 
media, the polymer matrix does not swell and drug release is controlled mainly 
by passive diffusion into the medium and the polymer plays an insignificant role 
in the drug release profile. If the drug is weakly bound to the surface of the NP, 
an initial burst release occurs [97]. In vitro drug release from chitosan NP usually 
show a two-step pattern with an initial rapid release followed by sustained release 
[101]. Patel et al. observed that rifampicin- chitosan NP presents a burst effect in 
the early stages followed by slow sustained drug release in which 90% of rifampicin 
was released in the range of 28–34 h. A good correlation fit was obtained between 
the cumulative drug released and square root of time, signifying that the drug 
release from the NP is diffusion-controlled as described by the Higuchi model. 
They concluded that rifampicin release from chitosan NP is pH dependent, i.e., 
faster at a lower pH than around neutral pH [102]. Similarly, Avadi et al. observed 
that insulin-loaded gum arabic/chitosan NP present a burst effect release in acidic 
medium, relating it to high solubility of both chitosan and insulin. No burst release 
was observed at higher pH values of 6.5 and 7.2. They concluded that the release 
followed a non-Fickian transport, governed by diffusion and/or swelling of the 
chitosan chains [103]. The performance of chitosan NP in the GIT depends on its 
response to the external milieu as discussed above. Equally important is how the 
GIT responds to the presence of NP. The following section describes the conse-
quence of NP deployment in the GIT in the management of selected diseases and 
expected responses.
4.4 Chitosan as an oral delivery vehicle for therapeutics
As mentioned in sections 4.1 and 4.2, extensive research presented the potential 
of chitosan as an oral absorption enhancer owing to its mucoadhesive properties 
and ability to loosen tight junctions within the GI epithelia, hence permitting the 
passage of macromolecular therapeutics across a “well-organised” epithelia [100]. 
Moreover, due to various characteristics; i.e. non-toxic, biodegradable, biocompat-
ible, antimicrobial property etc. [104], chitosan NP hold promise as a suitable oral 
delivery vehicle for a wide spectrum of therapeutics including, anti-cancer drugs, 
antibacterial agents, polyphenolic compounds and protein drugs.
4.4.1 Anti-cancer drug delivery
Chemotherapeutic APIs usually exhibit low bioavailability following oral admin-
istration. Several studies have investigated chitosan-based NP as a possible delivery 
system to address this issue. For example, doxorubicin (Dox), broadly employed 
to treat breast, bladder and other cancers, is typically delivered intravenously. The 
oral bioavailability of Dox is low due to efflux transporter P-glycoprotein, which 
identifies Dox as a substrate, restraining its cellular uptake [105]. In 2013, Feng et al. 
developed chitosan/o-carboxymethyl chitosan (CS/CMCS) NP as a pH responsive 
carrier for the oral delivery of Dox. They investigated the bioavailability of orally 
administered Dox-CS/CMCS NP and free Dox drug on Sprague–Dawley rats. 
Negligible Dox was detected in plasma after the oral dosage of free Dox, represent-
ing its poor absorption. On the other hand, 2.3-folds increase in plasma concen-
tration of Dox was registered after an oral dose of Dox-CS/CMCS NP. Moreover, 
accumulation of Dox in the liver, spleen and lungs were demonstrated in rats treated 
with oral Dox- CS/CMCS NP, as opposed to DoX solution which was more concen-
trated in the kidneys. They concluded that the NP matrix improved the intestinal 
absorption of Dox and thus improved oral bioavailability [106].
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Gemcitabine (Gem) is a widely prescribed anticancer agent used in pancreatic, 
lung and advanced colon cancer. Oral administration of Gem results in low oral 
bioavailability, high first-pass clearance gastrointestinal toxicity, such as nausea, 
vomiting and diarrhoea [107]. Hosseinzadeh et al. synthesised and characterised 
chitosan/Pluronic® F-127 (Gem-Chi/PF) NP in oral delivery of Gem for the 
treatment of colon cancer. In vitro studies showed that the NP presented enhanced 
cytotoxicity effects against HT-29 cell line and concluded that Gem-Chi/PF NP is a 
potential candidate for colon cancer treatment [108].
4.4.2 Anti-bacterial agent delivery
Chitosan impedes the growth of bacteria, fungi, and yeast [109]. It exhibits 
potential antimicrobial properties at pH below 6.0 because of the positively 
charged – NH3
+ at the C-2 position within the glucosamine. Low molecular weight 
chitosan derived NP integrate with bacterial DNA, impeding mRNA synthesis. 
Conversely, the NH3
+ in high molecular chitosan derived NP interact with the 
negatively-charged cell wall in microorganisms and subsequently amend cell 
permeability [110]. Alqahtani et al. formulated chitosan NP from high and low 
molecular weight variants to encapsulate the non-antibiotic diclofenac sodium 
(DIC). The antibacterial properties of NP from low and high molecular weight 
of chitosan on Staphylococcus aureus and Bacillus subtilis was significantly higher 
than from DIC alone. The antibacterial activity of chitosan was higher from the 
high molecular weight chitosan at pH = 5.5 [111]. In another in vitro study, Qi et al., 
investigated the antibacterial activity of chitosan NP and copper-loaded chitosan 
NP against various microorganisms (E. coli, S. choleraesuis, S. typhimurium and S. 
aureus). The antibacterial activity of chitosan NP and copper-loaded chitosan NP 
were significantly higher than from chitosan and doxycycline alone. Furthermore, 
copper-loaded NP indicated higher antibacterial activity against microorganism 
compared to chitosan NP void of copper. They concluded that this is due to the 
higher surface charge density of copper-loaded NP that improves the affinity of the 
cargo with the negatively charged bacteria membrane. Clearly, the antimicrobial 
property of chitosan is demonstrable and may augment the antibacterial effects of 
therapeutic antimicrobial when administered orally.
4.4.3 Polyphenolic compounds delivery
Secondary plant metabolites in the form of polyphenolic compounds have gained 
wide attention by scientists due to their wide spectrum of pharmacological activities, 
including antioxidant, antimicrobial and anticancer properties. Most however suffer 
from poor systemic bioavailability following oral administration due to low solubility 
and susceptibility to GI degradation. To overcome this constraint, chitosan-based NP 
have been proposed as a possible delivery intervention, which not only protect these 
APIs from GI degradation but also improves bioavailability [112]. Curcumin (CUR) 
is a polyphenol that has been studied extensively. It is derived from the rhizomes 
of Curcuma longa and active against a range of cancers in in vitro setups [113, 114]. 
However, preclinical and clinical data indicate that oral administration of CUR results 
in poor systemic bioavailability and high susceptibility to metabolic degradation [115]. 
In a study by AlKhader et al., the pharmacokinetic and anti-colon cancer properties 
of curcumin-containing chitosan-pectinate NP (CUR-CS-PEC-NPs) were evaluated. 
The cellular uptake and subsequent anti-proliferative effects of the CUR-CS-PEC-NPs 
were boosted at low CUR concentration after 48 and 72 hours of treatment compared 
to free CUR at equivalent dose. Besides, the carrier provided protection to CUR from 
acidic degradation. After oral administration of CUR-CS-PEC-NPs and free CUR at 
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10 mg/ml in rats a 4-fold increase in CUR concentration was detected compared to 
that of free CUR. Their findings indicated a null release of CUR in the upper GIT and 
a successful delivery of CUR to the colon with increased bioavailability of delivered 
CUR with time from CUR-CS-PEC-NPs for 24 h. Hence, rapid degradation metabo-
lism of free CUR was noticed at the same duration. They concluded that this formula-
tion may serve as a suitable delivery system for CUR to the colon in which CUR will be 
available on site for its chemotherapeutic activity against tumour [116].
4.4.4 Protein drug delivery
Proteins are the building blocks of life and required in replicating organisms. 
Their high molecular weight, chemical and enzymatic susceptibility in the GIT, low 
diffusion rate through the mucosa barrier and fast systemic clearance, limit their 
delivery via oral route. As a result, most proteins are administered parenterally. 
Fortunately, chitosan-based NP are emerging as promising means for the delivery of 
protein drugs by the oral route through a combination of shielding GI pH, enzymatic 
degradation and facilitation of epithelial uptake [117]. In a study by He et al., chito-
san-STPP insulin NP (CS/STPP/insulin) were orally administered to Type I diabetic 
rat models in comparison to free insulin solution. Free insulin solution failed to 
elicit any difference in the blood glucose level, whilst CS/STPP/insulin NP distinctly 
reduced the blood glucose levels by up to 59% within 8 hours. Crucially, CS/TPP/
insulin NP allowed for a fast recovery of blood sugar level when fasting was halted. 
Moreover, the CS/TPP/insulin NP exhibited negligible toxicity to liver enzymes, con-
firming the safety profile of the orally delivered CS/TPP/insulin NP. They concluded 
that CS/TPP NP are an effective oral delivery vehicle for insulin [118]. In another 
study, Tan et al. demonstrated better in vitro uptake and safety profile from ampho-
tericin B-containing chitosan coated nanostructured lipid carrier (ChiAmpB NLC) 
than from uncoated NLC [119]. The same authors later demonstrated better in vivo 
uptake from ChiAmpB NLC in rats than from uncoated NCL [120]. They attributed 
the observed increase in systemic bioavailability to increased mean absorption and 
mean residence times (MAT and MRT) from ChiAmpB NLC than from naked NLC. 
This was prompted by the mucoadhesive effect imposed by chitosan.
5. Conclusion
The oral route of administration remains formidable in the systemic delivery of 
therapeutics. It affords patient compliance, ease of administration and flexibility 
and remains the favourite choice for administration by patients. However, orally 
administered therapeutics may undergo premature release in the upper GIT which 
may render them to enzymatic or pH degradation. Therapeutics that are delivered to 
the absorptive window are susceptible to efflux pump and metabolic enzymes (e.g., 
cytochrome P450 enzymes) within the GIT epithelia, which is itself a structural bar-
rier. Scientist involved in the design of therapeutics intended for GI delivery must 
be cognizant of the above constraints and balance these with the physicochemical 
properties of the therapeutic. Recent evidence attest to the fact that appropriately 
formulated NP may be fit for this pursuit. In this regard, chitosan NP is the subject 
of intense interest because it is readily available, biocompatible, biodegradable, 
mucoadhesive and influences traversing of therapeutics across the GI epithelia. We 
expect to see more evidence on the application of chitosan in the oral delivery of 
therapeutics, especially in the form of NP. Further studies on toxicity related issues 
in vivo will assist in discerning any unanticipated effects in humans. These will pave 
the way for running clinical trials in humans in near future.
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